Real-World Effectiveness of Pembrolizumab as First-Line Therapy for Cisplatin-Ineligible Patients with Advanced Urothelial Carcinoma: the Aron-2 Study

AuthID
P-00Y-H1C
43
Author(s)
Santoni, M
·
Myint, ZW
·
Buettner, T
·
Takeshita, H
·
Okada, Y
·
Lam, ET
·
Gilbert, D
·
[+4]·
[+4]·
[+8]·
[+4]·
[+2]·
[+1]·
Rizzo, A
·
Monteiro, FSM
·
Battelli, N
·
Calabro, F
·
Porta, C
Document Type
Article in Press
Year published
2023
Published
in CANCER IMMUNOLOGY IMMUNOTHERAPY, ISSN: 0340-7004
Indexing
Publication Identifiers
Pubmed: 37248424
Scopus: 2-s2.0-85160408484
Wos: WOS:000999295300003
Source Identifiers
ISSN: 0340-7004
Export Publication Metadata
Marked List
Info
At this moment we don't have any links to full text documens.